I’m supporting Northwestern Memorial Foundation!
Northwestern Memorial Foundation raises funds to support the relentless pursuit of better medicine.
Northwestern Memorial Foundation raises funds to support the relentless pursuit of better medicine.
Artificial intelligence use in prostate cancer encompasses 4 main areas including diagnostic imaging, prediction of outcomes, histopathology, and treatment planning.
The introductions of immunotherapy and first-line combinations have led to major changes in systemic anti-cancer treatment (SACT) options and outcomes in metastatic renal cell carcinoma…
Thursday, May 23, 2024 12:00PM – 1:00PM ET Online Webinar will also be streamed virtually Register Today Watch the Friends x PICI May 6th Cell…
In recent years, Clinical Trials Day has become a chance to raise public awareness of the impact of research studies and to recognize the importance…
The FDA has withdrawn the approval of infigratinib for previously treated, FGFR2-positive, advanced cholangiocarcinoma.
Sarah Wilder wanted a way to give back while her husband received treatment at MD Anderson for stage IV prostate cancer. A blood drive provided…
Jubilee Brown, MD, highlights the RAS/MAPK pathway in low-grade serous ovarian cancer and research with avutometinib/defactinib that prompted RAMP 301.
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors. To access this subscriber-only content please log in…
This retrospective analysis of the PRODIGE-35 trial showed that LV5FU2 maintenance after 8 cycles of FOLFIRINOX is feasible in patients treated first line
Samilia Obeng-Gyasi, MD, MPH, expands on the impact of social determinants of health on breast cancer care.